AXQ Capital’s Aldeyra Therapeutics ALDX Stock Holding History

AXQ Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26,810	Closed	-$139K	–	986
2025 Q4	$139K	Buy	+26,810	New	+$138K	0.03%	622

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AXQ Capital's ALDX Position: Q1 2026 in Review

AXQ Capital sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 26,810 shares — an estimated $139K sold.

AXQ Capital first reported a position in ALDX in Q4 2025 and held it in 1 quarter. The position peaked at $139K in Q4 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

AXQ Capital reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 26,810 Aldeyra Therapeutics shares in Q1 2026, an estimated $139K.
AXQ Capital first reported a position in Aldeyra Therapeutics in Q4 2025 and held it in 1 quarter.
AXQ Capital's Aldeyra Therapeutics position peaked at $139K in Q4 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.